MedImmune chief, R&D head leave posts

MedImmune chief executive David Mott and the head of research and development, James Young, have resigned, just a year after AstraZeneca PLC's acquisition of the biotech firm. The unexpected departure of Mott, which takes effect at the end of July, and Young, who left his post earlier this month, deals another blow to AstraZeneca and reflects the challenges drugmakers face in keeping prime biotech talent on staff.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ